Medscape June 20, 2024
Kathleen Doheny

“My weight has always been kind of an issue,” said Gerald Fernandez, a 33-year-old mortgage broker in Naples, Florida. Over the years, he has sought advice from his physicians but felt unsatisfied with the guidance he has received: “They never gave me a solution, besides ‘Work out more, eat less.'”

Earlier this year, Fernandez found a new clinician who suggested he take a glucagon-like peptide 1 (GLP-1) receptor agonist for weight loss. He said he has lost about 20 lb in the 3 months he has been taking compounded semaglutide. But the medication is not the only difference-maker this time.

When Fernandez’s doctor, Yanet Diaz-Martell, MD, an internist and hospitalist at Physicians Regional Healthcare System in Naples, Florida, discussed his...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Patient / Consumer, Pharma / Biotech, Physician, Provider
JP Morgan Annual Healthcare Conference 2025: What are the key talking points likely to be?
Biden administration proposes Medicare coverage for weight loss drugs: 10 things to know
Proposed Coverage of Anti-Obesity Drugs in Medicare and Medicaid Would Expand Access to Millions of People with Obesity
Medicare and Medicaid would cover Ozempic, Wegovy under new Biden rule
New Proposal Aims to Expand Medicaid and Medicare Coverage for Obesity Drugs

Share This Article